Table 1:
Patient and tumor characteristics: NSABP B-42
| Placebo (n=1983) | Letrozole (n=1983) | |||
|---|---|---|---|---|
| Characteristic | n | % | n | % |
| Age at randomization, yrs | ||||
| <60 | 675 | 34.0 | 685 | 34.5 |
| ≥60 | 1308 | 66.0 | 1298 | 65.5 |
| Race | ||||
| White | 1840 | 92.8 | 1848 | 93.2 |
| Black | 81 | 4.1 | 70 | 3.5 |
| Asian | 39 | 2.0 | 39 | 2.0 |
| Other/Unknown | 23 | 1.2 | 26 | 1.3 |
| Pathologic Nodal Status | ||||
| Negative | 1134 | 57.2 | 1145 | 57.7 |
| Positive | 849 | 42.8 | 838 | 42.3 |
| Lowest BMD T-score | ||||
| ≤−2.0 | 493 | 24.9 | 489 | 24.7 |
| >−2.0 | 1490 | 75.1 | 1494 | 75.3 |
| Duration of Tamoxifen Prior to Randomization, mos | ||||
| 0 | 1212 | 61.1 | 1207 | 60.9 |
| 1 to 12 | 164 | 8.3 | 150 | 7.6 |
| 13 to 24 | 254 | 12.8 | 259 | 13.1 |
| 25 to 36 | 353 | 17.8 | 367 | 18.5 |
| Surgery Type | ||||
| Lumpectomy | 1208 | 60.9 | 1201 | 60.6 |
| Mastectomy | 775 | 39.1 | 782 | 39.4 |
| HER 2 Status | ||||
| Positive | 278 | 14.0 | 287 | 14.5 |
| Negative | 1547 | 78.0 | 1546 | 78.0 |
| Not done/Unknown | 158 | 8.0 | 150 | 7.6 |
| Duration of AI prior to randomization, mos* | ||||
| ≤36 | 412 | 20.8 | 399 | 20.1 |
| 37 to 48 | 192 | 9.7 | 207 | 10.4 |
| 49 to 60 | 992 | 50.0 | 970 | 48.9 |
| >60 | 387 | 19.5 | 407 | 20.5 |
*
Duration of AI for one patient in placebo group was unknown, presented in the “≤36” category.